Advisory OTCs? GSK Weighs Third Class Paradigm With Xenical In Mind
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline Consumer Healthcare is internally discussing the impact a third class of pharmacy-only drugs could have on the self-care market
You may also be interested in...
Xenical Rx-To-OTC Switch Filing Slated For 2005
GlaxoSmithKline will file for an Rx-to-OTC switch of Xenical (orlistat) a year earlier than expected
Xenical Rx-To-OTC Switch Filing Slated For 2005
GlaxoSmithKline will file for an Rx-to-OTC switch of Xenical (orlistat) a year earlier than expected
Xenical Rx-To-OTC Switch Filing Slated For 2005
GlaxoSmithKline will file for an Rx-to-OTC switch of Xenical (orlistat) a year earlier than expected